571 related articles for article (PubMed ID: 26845108)
1. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A; Scheckel B; Habsaoui A; Haque M; Kuhr K; Monsef I; Bohlius J; Skoetz N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD012633. PubMed ID: 35724934
[TBL] [Abstract][Full Text] [Related]
3. Early erythropoiesis-stimulating agents in preterm or low birth weight infants.
Ohlsson A; Aher SM
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004863. PubMed ID: 29145693
[TBL] [Abstract][Full Text] [Related]
4. Early erythropoiesis-stimulating agents in preterm or low birth weight infants.
Ohlsson A; Aher SM
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD004863. PubMed ID: 32048730
[TBL] [Abstract][Full Text] [Related]
5. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
[TBL] [Abstract][Full Text] [Related]
6. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
[TBL] [Abstract][Full Text] [Related]
7. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.
Kaufner L; von Heymann C; Henkelmann A; Pace NL; Weibel S; Kranke P; Meerpohl JJ; Gill R
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012451. PubMed ID: 32790892
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
10. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Aher SM; Ohlsson A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD004868. PubMed ID: 30776084
[TBL] [Abstract][Full Text] [Related]
11. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Aher SM; Ohlsson A
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD004868. PubMed ID: 31990982
[TBL] [Abstract][Full Text] [Related]
12. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Estcourt LJ; Malouf R; Trivella M; Fergusson DA; Hopewell S; Murphy MF
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011305. PubMed ID: 28128441
[TBL] [Abstract][Full Text] [Related]
13. Harms of off-label erythropoiesis-stimulating agents for critically ill people.
Mesgarpour B; Heidinger BH; Roth D; Schmitz S; Walsh CD; Herkner H
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010969. PubMed ID: 28841235
[TBL] [Abstract][Full Text] [Related]
14. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Radford M; Estcourt LJ; Sirotich E; Pitre T; Britto J; Watson M; Brunskill SJ; Fergusson DA; Dorée C; Arnold DM
Cochrane Database Syst Rev; 2024 May; 5(5):CD011305. PubMed ID: 38780066
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
16. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
[TBL] [Abstract][Full Text] [Related]
17. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
19. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
